Sign In
Buy COGT
$32.26
-0.500 (-1.53%)
At Close: Jun 03, 2026
Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript
03:07pm, Wednesday, 03'rd Sep 2025
Cogent Biosciences, Inc. (NASDAQ:COGT ) Citi's Biopharma Back to School Conference September 3, 2025 9:00 AM EDT Company Participants Andrew Robbins - President, CEO & Director Conference Call Partici
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
08:00am, Tuesday, 26'th Aug 2025
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
08:00am, Tuesday, 05'th Aug 2025
Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endp
2 Biotech and 2 Tech Stocks Insiders Are Scooping Up Now
08:45am, Wednesday, 23'rd Jul 2025
Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.
WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results
04:04pm, Wednesday, 09'th Jul 2025
I have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
09:36pm, Tuesday, 08'th Jul 2025
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
04:26pm, Tuesday, 08'th Jul 2025
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
11:56am, Tuesday, 08'th Jul 2025
Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.
Why Is Cogent Biosciences Stock Trading Higher On Monday?
09:22am, Monday, 07'th Jul 2025
Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder.
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
08:00am, Wednesday, 11'th Jun 2025
Facility provides additional funding for next steps of the Company's growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, begi
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
WALTHAM, Mass. and BOULDER, Colo.
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
11:01am, Tuesday, 13'th May 2025
The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Cogent Biosciences Reports First Quarter 2025 Financial Results
08:00am, Tuesday, 06'th May 2025
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected
